The best mesothelioma surgery is the one the patient can tolerate with the fewest serious side effects. That’s according to a new study from MD Anderson researchers. Their goal was to help settle the ongoing debate over which type of pleural mesothelioma surgery is most effective. Both EPP and P/D surgery are major operations. But one causes much more serious side effects than the other. So how do doctors and patients decide on the best mesothelioma surgery for their case? The new research suggests there may not be a definitive answer. Debate Over the Best Mesothelioma Surgery Pleural mesothelioma is an asbestos-linked cancer of the membrane around the lungs. During EPP (extrapleural pneumonectomy) surgery, doctors remove this membrane, any other … Continue reading Study Asks What is the Best Mesothelioma Surgery?
Japanese researchers say P/D surgery for mesothelioma improves quality of life for most patients, even if their lung function gets worse. Doctors at the Hyogo College of Medicine tracked the cases of forty-five patients who had P/D surgery for mesothelioma between 2014 and 2018. Lung function tests showed most pleural mesothelioma patients could not breathe as well after surgery as they did before. Their energy, vitality, and social functioning also decreased. But patients reported better mental health after surgery and significantly less pain. The researchers conclude that quality of life after P/D surgery for mesothelioma may have less to do with breathing than previously thought. What is P/D Surgery for Mesothelioma? Pleural mesothelioma tumors grow on the pleura, a thin … Continue reading P/D Surgery for Mesothelioma Improves Quality of Life Regardless of Lung Function
A mesothelioma treatment called NIPEC may help people with peritoneal mesothelioma live longer than expected. In some cases, much longer. A recent study of 74 peritoneal mesothelioma patients showed a combination of cytoreductive surgery (CRS), HIPEC, and NIPEC works better than CRS/HIPEC alone. The study comes from one of the country’s foremost medical authorities on peritoneal mesothelioma. Dr. Paul Sugarbaker runs the Peritoneal Surface Malignancy Program at Washington Cancer Institute in Washington, DC. Last year, Dr. Sugarbaker released results of a small study on NIPEC treatment for mesothelioma. Although that study included only six patients, the results were impressive enough to warrant further study. This year’s larger NIPEC study is even more promising for people fighting mesothelioma. Similarities and DIfferences … Continue reading NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival?
The two major types of mesothelioma surgeries carry similar risk of death, according to a new study from cancer researchers in Japan. One surgery involves removing the diseased pleural lining and one of the lungs. The other surgery removes many of the same tissues but leaves the lungs intact. Surgeons around the world are divided as to which of these mesothelioma surgeries is best. Mesothelioma patients have more complications with lung-removing surgery. But some studies suggest it could lead to longer survival. The 4-year Japanese study included more than 600 patients. It suggests that the likelihood of dying is similar with either of these mesothelioma surgeries. Surgical Treatment of Pleural Mesothelioma Pleural mesothelioma is the most common type of asbestos … Continue reading Mesothelioma Surgeries Carry Similar Mortality Risk, Study Finds
A group of European pathologists say the different mesothelioma subtypes have significant differences in their pattern of gene expression. Exploiting these differences could help scientists craft more effective mesothelioma treatments. Asbestos exposure is the primary cause of mesothelioma. But doctors know that genetics play a role, too. Newly-approved immunotherapy drugs target proteins expressed by specific genes. But these drugs work much better in some mesothelioma patients than they do in others. The new study suggests that differences in the genetic profiles of different mesothelioma subtypes could help explain why. Immunotherapy Drugs for Mesothelioma Immunotherapy is an up-and-coming treatment approach for mesothelioma and other cancers. It harnesses the power of the person’s immune system to fight cancer. In people with mesothelioma, … Continue reading Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments
The plight of an LA actress who found out she had lung cancer because of a COVID test is a sobering reminder to be aware of the early signs of pleural mesothelioma. The woman’s story was recently featured on the Today Show website. Fifty-nine year old Annabelle Gurwitch is a non-smoker with no known lung cancer risk factors. She and her 23-year-old child decided to get COVID tests after her child came home from college. Although the COVID test was negative, Gurwitch writes that doctors were concerned about her persistent cough. Ongoing cough can be a one of the early signs of pleural mesothelioma, too. An X-ray revealed that Gurwitch was suffering from Stage 4 lung cancer, the most common … Continue reading LA Woman’s Story is a Sobering Reminder to Watch for Signs of Pleural Mesothelioma
The first patient has been treated in the trial of a new drug that might help people suffering from mesothelioma-related weight loss. The drug is a synthetic cannabinoid called ART27.13. A cannabinoid is a compound that acts on the CB1 and CB2 receptors of the endocannabinoid system. There are a number of cannabinoid drugs on the market. But several of them have significant side effects, including effects on the brain. Preclinical data on ART27.13 suggest that it may stimulate the appetite and counter mesothelioma-related weight loss with fewer unwanted side effects. The Cancer Appetite Recovery Study (CAReS) is a Phase I trial to test it in people. The Danger of Mesothelioma-Related Weight Loss Over 60 percent of late-stage cancer patients … Continue reading Mesothelioma-Related Weight Loss: Synthetic Cannabinoid Might Help
A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant pleural mesothelioma. Pleural mesothelioma is an intractable cancer with a poor prognosis. It mainly affects people who have lived or worked around asbestos. There is no cure for mesothelioma. People who have the best mesothelioma outcomes usually have a combination of treatments. Now, scientists at Toronto General Hospital’s Research Institute say a triple-modality therapy they tested in mice might have the power to extend human lives, too. Multi-modal Mesothelioma Treatment Pleural mesothelioma is a fast-growing cancer that starts on the membrane around the lungs. Many mesothelioma patients die less than a year after diagnosis. There is no single accepted treatment … Continue reading Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests
An immunotherapy combination of tremelimumab and durvalumab has resulted in long-term survival for some mesothelioma patients in a new follow-up Italian study. Tremelimumab and durvalumab (Imfinzi) received orphan drug designation from the FDA last year for liver cancer. Now, it looks like this immunotherapy combination could help some people with the rare asbestos cancer, too. Mesothelioma patients who had the best results in the new study were those with a high number of mutated genes. Mesothelioma is often fatal within a year. But the longest-living patient in the study survived for more than 41 months. Immunotherapy Combination Blocks Key Proteins White blood cells have the power to help combat mesothelioma. But a protein called CTLA-4 can block that ability. Tremelimumab … Continue reading Long-Term Mesothelioma Survival With Immunotherapy Combination
Research at MIT suggests that an inhaled vaccine may trigger a strong immune response against infections and even cancer in the lungs. The findings could be good news for people at risk for the rare lung-related cancer, pleural mesothelioma. Lung infections often start on mucosal membranes. So researchers developed a vaccine that binds to a protein in mucus. When they immunized mice in a way that mimics an inhaled vaccine, their lungs produced many T-cells. T-cells are immune system cells that can help fight infections and cancer. Pleural mesothelioma is caused by exposure to asbestos. Right now, there is no way to vaccinate against it and no cure. If an inhaled vaccine could bring more T-cells to the lungs of … Continue reading Could an Inhaled Vaccine Help Prevent Mesothelioma?